PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
J Health Care Poor Underserved. Author manuscript; available in PMC 2013 September 30.
Published in final edited form as:
J Health Care Poor Underserved. 2012 May; 23(2): 811–833.
doi: 10.1353/hpu.2012.0047

Table 1

Distribution of hepatitis C antibody for the total sample and by site stratified by Injection Drug Use History (N=387).




Study Site
Sample sizeHCV Prevalence



% N
Injection Drug UsersHCV
Prevalence
among
non- injectors
% N
Injectors as % of
sample
% N
HCV Prevalence
among injectors
% N
Injectors as % of
all HCV+
%
Total HCH Sites
Ages 18+
387 31.0% (120) 28.4% (110) 70.0% (77) 64.2% 15.5% (43)
Providence, RI4847.9% (23)45.8% (22)81.8 (18)78.319.2(5)
Phoenix, AZ5034.0% (17)28.0 (14)%78.6 (11)64.721.4 (3)
Birmingham, AL4628.3% (13)19.6% (9)77.8 (7)53.816.2 (6)
Milwaukee, WI 5018.0% (9)16.0% (8)75.0 (6)66.77.1 (3)
Albuquerque, NM4936.7% (18)34.7% (17)70.6(12)66.718.8 (12)
Los Angeles, CA4628.3% (13)17.4% (8)62.5 (5)38.521.1 (8)
Des Moines, IA4825.0% (12)29.2% (14)57.1 (8)66.711.8 (4)
Denver, CO5030.0% (15)36.0% (18)55.6 (10)66.715.6 (5)

Note: Prevalence of HCV varied only marginally by site (p<.10). Prevalence of injection drug use and prevalence of HCV among injectors varied significantly by site (p<.05).